Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Christina von Hunolstein is active.

Publication


Featured researches published by Christina von Hunolstein.


Journal of Clinical Microbiology | 2004

Multiplex PCR Assay for Direct Identification of Group B Streptococcal Alpha-Protein-Like Protein Genes

Roberta Creti; Francesca Fabretti; Graziella Orefici; Christina von Hunolstein

ABSTRACT We developed a group B streptococcus multiplex PCR assay which allows, by direct analysis of the amplicon size, determination of the surface protein antigen genes of alpha-C protein, epsilon protein, Rib, Alp2, Alp3, and Alp4. The multiplex PCR assay offers a rapid and simple method of subtyping Streptococcus agalactiae based on surface protein genes.


The Journal of Infectious Diseases | 2000

Severity of Group B Streptococcal Arthritis Is Correlated with β-Hemolysin Expression

Manuela Puliti; Victor Nizet; Christina von Hunolstein; Francesco Bistoni; Paolo Mosci; Graziella Orefici; Luciana Tissi

Septic arthritis is a clinical manifestation of group B streptococcal (GBS) infection in neonates and adults. To examine the potential role of GBS beta-hemolysin in joint injury, mice were infected with 2 wild-type strains or with nonhemolytic (NH) or hyperhemolytic (HH) variants derived by transposon mutagenesis. Compared with mice infected with the parent strains, mice infected with the NH mutants had decreased mortality and bacterial proliferation. A reduced LD(50) and a higher microbial load were obtained in mice infected with the HH mutants. Greater degrees of joint inflammation and damage were observed in the HH mutant-infected animals than in those infected with the parental strains. NH mutant-infected mice manifested only a mild and transient arthritis. Systemic and local levels of interleukin-6 mirrored the observed differences in virulence and severity of arthritis. These data support a direct correlation of GBS beta-hemolysin expression with mortality and severity of articular lesions.


Carbohydrate Research | 1995

STRUCTURAL ELUCIDATION OF THE NOVEL TYPE VII GROUP B STREPTOCOCCUS CAPSULAR POLYSACCHARIDE BY HIGH RESOLUTION NMR SPECTROSCOPY

Grigorij Kogan; Jean-Robert Brisson; Dennis L. Kasper; Christina von Hunolstein; Graziella Orefici; Harold J. Jennings

The type VII capsular polysaccharide isolated from the newly discovered group B Streptococcus (GBS) strain contains D-glucose, D-galactose, N-acetyl-D-glucosamine and N-acetylneuraminic acid in the molar ratio 2:2:1:1. High-resolution one- and two-dimensional (1D and 2D) 1H and 13C NMR spectroscopy of the native and desialylated polysaccharides showed the type VII GBS capsular polysaccharide to contain the following branched hexasaccharide repeating unit: [formula: see text] Despite extensive structural similarity with the previously described GBS polysaccharides, the type VII polysaccharide showed no cross-reaction with the heterologous antisera.


Infection and Immunity | 2002

Regulatory role of interleukin-10 in experimental group B streptococcal arthritis

Manuela Puliti; Christina von Hunolstein; Claudie Verwaerde; Francesco Bistoni; Graziella Orefici; Luciana Tissi

ABSTRACT Intravenous inoculation of CD-1 mice with 107 CFU of type IV group B Streptococcus (GBS) results in a high incidence of diffuse septic arthritis , associated with high levels of systemic and local production of interleukin-1β (IL-1β) and IL-6. In this study, the role of the anti-inflammatory cytokine IL-10 in the evolution of GBS systemic infection and arthritis was evaluated. IL-10 production was evident in sera and joints of GBS-infected mice. Neutralization of endogenous IL-10 by administration of anti-IL-10 antibodies (1 mg/mouse) at the time of infection resulted in worsening of articular lesions and 60% mortality associated with early sustained production of IL-6, IL-1β, and tumor necrosis factor alpha (TNF-α). The effect of IL-10 supplementation was assessed by administering IL-10 (100, 200, or 400 ng/mouse) once a day for 5 days, starting 1 h after infection. Treatment with IL-10 had a beneficial effect on GBS arthritis, and there was a clear-cut dose dependence. The decrease in pathology was associated with a significant reduction in IL-6, IL-1β, and TNF-α production. Histological findings showed limited periarticular inflammation and a few-cell influx in the articular cavity of IL-10-treated mice, confirming clinical observations. In conclusion, this study provides further information concerning the role of IL-10 in regulating the immune response and inflammation and calls attention to the potential therapeutic use of IL-10 in GBS arthritis.


Vaccine | 2001

The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti-Haemophilus influenzae type b glycoconjugates into efficient anti-polysaccharide and anti-carrier polyvalent vaccines

Christina von Hunolstein; Sabrina Mariotti; Raffaela Teloni; Giovanna Alfarone; Giulia Romagnoli; Graziella Orefici; Roberto Nisini

Synthetic oligodeoxynucleotides containing CpG immunostimulatory sequences (ISS) have been shown to act as potent adjuvants of type 1 immune responses when co-administered with protein or peptide vaccines. We have recently shown that ISS can increase the anti-polysaccharide (CHO) and anti-tetanus toxoid (TT) or anti-diphtheria (CRM) toxoid antibody levels if used as adjuvant of anti-Haemophilus influenzae type b (Hib) CHO vaccine conjugated with TT or CRM. The analysis of anti-TT and anti-CRM IgG subclasses showed a significant increase in IgG2a, IgG2b and/or IgG3 in the presence of ISS. Anti-TT and anti-CRM antibodies were shown to neutralize the activity of both the tetanus and diphtheria toxin in vivo or in vitro tests respectively. These data show that ISS have the potential to increase host antibody response against both the CHO and the protein component of a conjugated vaccine, and encourage the investigation to identify strategies of vaccination with schedules aimed at the valuation of protein carriers as protective immunogens.


Vaccine | 2002

Immunogenicity of anti-Haemophilus influenzae type b CRM197 conjugate following mucosal vaccination with oligodeoxynucleotide containing immunostimulatory sequences as adjuvant.

Sabrina Mariotti; Raffaela Teloni; Christina von Hunolstein; Giulia Romagnoli; Graziella Orefici; Roberto Nisini

Most vaccines are delivered by injection. Mucosal vaccination would increase compliance and decrease the risk of spread of infectious diseases due to a reduction of mucosal colonization and of contaminated syringes. However, most vaccines are unable to induce immune responses when administered mucosally, and require the use of strong adjuvant or effective delivery systems. Synthetic oligodeoxynucleotides (ODN) containing CpG immunostimulatory sequences (ISS) have been shown to act as potent adjuvants of type-1 immune responses also when mucosally co-administered with protein or peptide vaccines. We have shown that ISS can increase the anti-polysaccharide polyribosyl ribitol phosphate (PRP) antibody titres and anti-diphtheria toxin neutralizing antibody, if used as adjuvant of anti-Haemophilus influenzae type b (Hib) PRP vaccine conjugated with cross-reacting material (CRM) of diphtheria toxin in mice. Here, we show that ISS have the potential to increase host local and systemic antibody response against both the PRP and the protein component of a conjugated vaccine when mucosally administered in mice. Mucosal administration of Hib-CRM vaccine induced anti-PRP and neutralizing anti-diphtheria toxin antibodies of all the IgG subclasses, with a predominance of type-1 immune response-associated IgG2a and IgG3. At odds with systemic administration, the mucosal delivery of Hib-CRM induced anti-PRP and anti-diphtheria toxin mucosal IgA. These data envisage the feasibility of a mucosal vaccination with an already licensed Hib-CRM vaccine to achieve both an anti-H. influenzae and -diphtheria effective protection.


Vaccine | 2014

Tetanus in Italy 2001-2010: a continuing threat in older adults.

Antonietta Filia; Antonino Bella; Christina von Hunolstein; Antonella Pinto; Giovanna Alfarone; Silvia Declich; Maria Cristina Rota

Despite being a completely preventable disease, tetanus cases continue to occur in Italy and notification and hospitalization rates have been reported to be higher with respect to European and other industrialized countries. We examined statutory notification, hospitalization, mortality and seroprevalence data to describe tetanus epidemiology in Italy from 2001 to 2010. A total of 594 tetanus cases were notified, with an average annual incidence of 1.0/1,000,000 population. Most cases were unvaccinated or incompletely vaccinated. Eighty percent of cases occurred in subjects aged >64 years and a higher proportion of females with respect to males were reported in this age group. The annual number of hospital admissions was 1.4-1.7 times greater than the number of notifications in the same year. The mean annual number of reported deaths was 21. Seroprevalence data show progressively higher susceptibility levels with increasing age. Over 50% of persons aged 45-64 years and over two thirds of subjects ≥65 years had tetanus antibody levels <0.01 IU/ml. Results show that tetanus is a continuing problem in Italy and, as in other countries, most cases occur in older adults, especially elderly women. The observed differences in notification and hospitalization rates suggest underreporting by physicians. In recent years, Italy has accounted for most cases reported annually in the European Union (EU) but different case definitions are used. In Italy, a confirmed case is one that meets the clinical case definition while the EU case definition classifies confirmed cases as those with laboratory confirmation of disease. The incidence of clinical tetanus in Italy is ten-fold higher than in other industrialized countries, like Australia and Canada, likely due to higher susceptibility levels in Italy. In view of the low prevalence of tetanus antibodies in adults ≥45 years, strategies to improve vaccine uptake in this population group need to be implemented.


Cellular Microbiology | 2002

Role of macrophages in experimental group B streptococcal arthritis

Manuela Puliti; Christina von Hunolstein; Francesco Bistoni; Roberto Castronari; Graziella Orefici; Luciana Tissi

Septic arthritis is a clinical manifestation of group B Streptococcus (GBS) infection in both neonates and adults. Because macrophages are known to participate in tissue injury, the role of this cell population in GBS‐induced arthritis was investigated. Mice were rendered monocytopenic by administration of etoposide, a drug that selectively depletes the monocyte/macrophage population and then injected with GBS (1u2003×u2003107 colony‐forming units per mouse). Appearance of arthritis, mortality, GBS growth in the organs, and local and systemic cytokine production were examined. Etoposide‐treated mice had a significantly less severe arthritis than control animals. Histopathological analysis of the joints confirmed clinical observations. Decreased joint levels of the proinflammatory cytokines interleukin 1 (IL‐1) beta and IL‐6 accompanied the less severe development of arthritis in monocytopenic mice. In contrast, mortality was increased in the etoposide‐treated mice compared with controls. Monocytopenic mice exhibited elevated bacterial load in the blood and kidneys at all time points exam‐ined. These results indicate that lack of macrophages leads to less severe joint lesions, but also results in impaired clearance of bacteria, and consequent enhancement of mortality rates.


Infection and Immunity | 2000

Human Monocyte Receptors Involved in Tumor Necrosis Factor Responses to Group B Streptococcal Products

Maria Cuzzola; Giuseppe Mancuso; Concetta Beninati; Carmelo Biondo; Christina von Hunolstein; Graziella Orefici; Terje Espevik; Trude H. Flo; Giuseppe Teti

ABSTRACT Several group B streptococcal products have been previously found to stimulate human monocytes to produce tumor necrosis factor alpha. In order to identify the receptors involved in these responses, monocytes were stimulated with purified group- or type-specific carbohydrates or lipoteichoic acid in the presence of anti-receptor monoclonal antibodies, soluble CD14, or lipopolysaccharide-binding protein. Results indicate that CD14 plays an important role in tumor necrosis factor alpha responses to all of the stimuli tested. Moreover, both CD14 and complement receptor type 3 may be involved in responses to the group-antigen.


Journal of Carbohydrate Chemistry | 1994

Structure of the Type VI Group B Streptococcus Capsular Polysaccharide Determined by High Resolution NMR Spectroscopy

Grigorij Kogan; Dušan Uhrín; Jean-Robert Brisson; Lawrence C. Paoletti; Dennis L. Kasper; Christina von Hunolstein; Graziella Orefici; Harold J. Jennings

Abstract The structure of the capsular polysaccharide of the recently characterized type VI Group B Streptococcus (GBS) has been established using one- and two-dimensional homo- and heterocorrelated 1H and 13C NMR spectroscopy. The native polysaccharide contains D-glucose, D-galactose and sialic acid in the molar ratio 2:2:1. The structure of its repeating unit is:

Collaboration


Dive into the Christina von Hunolstein's collaboration.

Top Co-Authors

Avatar

Graziella Orefici

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Antonella Pinto

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Raffaela Teloni

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Roberto Nisini

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Sabrina Mariotti

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Giovanna Alfarone

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge